

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5494769

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
GLORIANA THERAPEUTICS SARL	04/26/2019

RECEIVING PARTY DATA

Name:	GLORIANA THERAPEUTICS, INC.
Street Address:	225 CHAPMAN STREET
Internal Address:	SUITE 201
City:	PROVIDENCE
State/Country:	RHODE ISLAND
Postal Code:	02905

PROPERTY NUMBERS Total: 23

Property Type	Number
Application Number:	12280772
Application Number:	16230216
Application Number:	15291257
Application Number:	14760182
Application Number:	15544482
Patent Number:	7442370
Patent Number:	8119114
Patent Number:	7598059
Patent Number:	8163875
Patent Number:	8642732
Patent Number:	9138461
Patent Number:	8329655
Patent Number:	8263553
Patent Number:	6593133
Patent Number:	8217146
Patent Number:	6734284
Patent Number:	7358228
Patent Number:	7655463
Patent Number:	7276580

PATENT

Property Type	Number
Patent Number:	8722862
Patent Number:	10047150
Application Number:	12281077
Application Number:	12672213

CORRESPONDENCE DATA

Fax Number: (857)300-4001

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Email: skerner@lathropgage.com

Correspondent Name: ANN-LOUISE KERNER

Address Line 1: 28 STATE STREET

Address Line 2: SUITE 0700

Address Line 4: BOSTON, MASSACHUSETTS 02109

ATTORNEY DOCKET NUMBER:	101893
NAME OF SUBMITTER:	ANN-LOUISE KERNER
SIGNATURE:	/Ann-Louise Kerner/
DATE SIGNED:	04/26/2019

Total Attachments: 4

source=Gloriana SARL to INC assignment#page1.tif

source=Gloriana SARL to INC assignment#page2.tif

source=Gloriana SARL to INC assignment#page3.tif

source=Gloriana SARL to INC assignment#page4.tif

ASSIGNMENT

WHEREAS, Gloriana Therapeutics SARL, a corporation having its principal place of business at Avenue Du Secheron 15, Geneve 1202, Switzerland, is the owner by assignment of certain patent applications and granted patents identified in Appendix A (hereinafter "INVENTIONS"); and

WHEREAS, Gloriana Therapeutics, Inc., a corporation having its principal place of business at 225 Chapman Street, Suite 201, Providence, Rhode Island 02905, United States, is desirous of acquiring all rights, title and interests in and to said inventions, said applications, and in and to any and all Letters Patent which may be granted for or upon said invention and applications in the United States of America and all countries foreign thereto.

NOW THEREFORE, to all whom it may concern, be it known that for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Gloriana Therapeutics SARL has sold, assigned and transferred, and by these presents to sell, assign and transfer unto the said Gloriana Therapeutics, Inc. the full and exclusive right, title and interest, throughout the world, in, to and under the following:

- (a) said inventions as fully set forth and described in the Appendix A prepared;
- (b) said applications and patents in Appendix A;
- (c) any and all refilings, divisions, continuations and continuations-in-part of said applications and patents in Appendix A;
- (d) any and all Letters Patent of the United States of America which may issue from said applications, refilings, divisions, continuations and continuations-in-part;
- (e) any and all reissues and reexaminations of said Letters Patent of the United States of America;
- (f) any and all applications for Letters Patent upon said invention which may hereafter be filed in any and all countries foreign to the United States of America;
- (g) any and all refilings, divisions and continuations of said foreign-filed applications;
- (h) all claims, causes of action and damages for past infringement, if any, of said application;
- (i) any and all Letters Patent of countries foreign to the United States of America which may issue from the said foreign-filed applications, refilings, divisions and continuations; and
- (j) any and all extensions of, and additions to, said Letters Patent of countries foreign to the United States of America.

Gloriana Therapeutics SARL further agree that upon request it will provide promptly all pertinent facts and documents relating to said invention and said Letters Patent and legal equivalents as may be known and accessible and will testify as to the same in any interference, litigation or proceeding related thereto and will promptly execute and deliver to Gloriana Therapeutics, Inc. or its legal representatives any and all papers, instruments or affidavits required to apply for, obtain, maintain, issue and enforce said application, said invention and said Letters Patent and said equivalents thereof which may be necessary or desirable to carry out the purposes thereof.

ALL of the above shall be held and enjoyed by the said Gloriana Therapeutics, Inc. for its own use and benefit, and for its successors, legal representatives and assigns, to the full end of the term for which said applications and Letters Patent may be granted, and do hereby authorize and request the Commissioner of Patents and Trademarks to issue the said Letters Patent in accordance with this Assignment.

Gloriana Therapeutics SARL

Jan Wahlberg
Signature

JAN WAHLBERG
Name

CEO
Title

Signed in my presence and acknowledged to be an assignment of the application herein above referred to:

WITNESS

Norton, MA
Signed At (City/State)

DWANE EMERICH
Name

[Signature]
Signature

26 Apr 2019
Date

WITNESS

Norton, MA
Signed At (City/State)

Robert Platt
Name

[Signature]
Signature

26 Apr 2019
Date

APPENDIX A

IP Ref No	Title	Application No	Patent No
NSG-011EP	Treatments For Neurological Disorders	07752089.8	1993589
NSG-011EPCH	Treatments For Neurological Disorders	07752089.8	1993589
NSG-011EPDE	Treatments For Neurological Disorders	07752089.8	1993589
NSG-011EPES	Treatments For Neurological Disorders	07752089.8	1993589
NSG-011EPGB	Treatments For Neurological Disorders	07752089.8	1993589
NSG-011US	Treatments For Neurological Disorders	12/280,772	
NSG-012CONCIP	Mammalian Cell Culture-Produced Neublentin Antibodies	16/230,216	
NSG-012US	Medium Supplements for Improved Process Performance	15/291,257	
NSG-012US	Medium Supplements for Improved Process Performance	14/760,182	
NSG-013EP	Therapeutic Protein Formulations	16703658.1	
NSG-013US	Therapeutic Protein Formulations	15/544,482	
NSG-014	Polymer Conjugates of Mutated Neublentin	10/356,264	7,442,370
NSG-014CA	Polymer Conjugates of Mutated Neublentin	2514510	2514510
NSG-014CN	Polymer Conjugates of Mutated Neublentin	201110239061.X	
NSG-014CON	Polymer Conjugates of Mutated Neublentin	12/163,425	8,119,114
NSG-014EP	Polymer Conjugates of Mutated Neublentin	20040707363	1594436
NSG-014EPCH	Polymer Conjugates of Mutated Neublentin	20040707363	1594436
NSG-014EPDE	Polymer Conjugates of Mutated Neublentin	20040707363	1594436
NSG-014EPDIV	Polymer Conjugates of Mutated Neublentin	20100173737	2246362
NSG-014EPGB	Mutated Neublentin	20040707363	1594436
NSG-014EPIE	Mutated Neublentin	20040707363	1594436
NSG-014JP	Polymer Conjugates of Neublentin and Methods of Using Same	20020561497	4259868
NSG-015	Neublentin Expression Constructs	10/957,221	7,598,059
NSG-015EPDE	Improved Secretion Of Neublentin	04736510.1	1636260
NSG-015EPDE2	Improved Secretion Of Neublentin	09153016.2	2058329
NSG-015EPFR	Improved Secretion Of Neublentin	04736510.1	1636260
NSG-015EPFR2	Improved Secretion Of Neublentin	09153016.2	2058329
NSG-015EPGB	Improved Secretion Of Neublentin	04736510.1	1636260
NSG-015EPGBDIV	Improved Secretion Of Neublentin	09153016.2	2058329
NSG-015EPIE	Improved Secretion Of Neublentin	04736510.1	1636260
NSG-017US	Polymer-Conjugated Glycosylated Neublentin	10/553,710	8,163,875
NSG-017USCON	Polymer-Conjugated Glycosylated Neublentin	13/425,583	8,642,732
NSG-018DIV	Compositions And Methods For Increasing Vascularization	13/679,529	9,138,461
NSG-018EPDE	Neublentin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	08747382.3	2142205
NSG-018EPFR	Neublentin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	08747382.3	2142205
NSG-018EPGB	Neublentin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	08747382.3	2142205

NSG-018EPIE	Neublastin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	08747382.3	2142205
NSG-018EPSE	Neublastin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	08747382.3	2142205
NSG-018PCT	Methods For Increasing Vascularization	12/598,293	8,329,655
NSG-018PCTJP	Neublastin Peptides For Use In Increasing Vascularisation In Tissue With Impaired Blood Flow	2010-506645	5583005
NSG-019CH	Neublastin Variants	05789285.3	1786454
NSG-019DE	Neublastin Variants	602005022457.2	1786454
NSG-019DEDIV	Neublastin Variants	602005044319.3	2238983
NSG-019EP	Neublastin Variants	20050789285	1786454
NSG-019EPDIV	Neublastin Variants	10170146.4	2238983
NSG-019ES	Neublastin Variants	20050789285	1786454
NSG-019FR	Neublastin Variants	20050789285	1786454
NSG-019FRDIV	Neublastin Variants	10170146.4	2238983
NSG-019GB	Neublastin Variants	05789285.3	1786454
NSG-019GBDIV	Neublastin Variants	10170146.4	2238983
NSG-019IE	Neublastin Variants	05789285.3	1786454
NSG-019US	Neublastin Variants	11/573,773	8,263,553
NSG-021	Novel Therapeutic Factors	09/347,613	6,593,133
NSG-021CON	Neurotrophic Factors and Methods of Use Thereof	12/632,517	8,217,146
NSG-021DIV	Novel Neurotrophic Factors	09/662,183	6,734,284
NSG-021DIV	Novel Neurotrophic Factors	11/614,599	7,358,228
NSG-021DIV2	Novel Neurotrophic Factors	12/029,917	7,655,463
NSG-021PCCON	Novel Neurotrophic Factors	10/661,984	7,276,580
NSG-022EP	Refolding Transforming Growth Factor Beta Family Proteins	05789270.5	1784203
NSG-022EPDE	Refolding Transforming Growth Factor Beta Family Proteins	05789270.5	1784203
NSG-022EPFR	Refolding Transforming Growth Factor Beta Family Proteins	05789270.5	1784203
NSG-022EPGB	Refolding Transforming Growth Factor Beta Family Proteins	05789270.5	1784203
NSG-022EPIE	Refolding Transforming Growth Factor Beta Family Proteins	05789270.5	1784203
NSG-022US	Refolding Transforming Growth Factor Beta Family Proteins	11/573,771	8,722,862
NSG-024CON	Anti-Neublastin Antibodies And Uses Thereof	14/589,372	10,047,150
NSGE-020US	Compositions and Methods for Administering GDNF Ligand Family Proteins	12/281,077	
NSGE-023CA	Characterization Of Cysteine Knot Superfamily Proteins		
NSGE-024US	Anti-Neublastin Antibodies And Uses Thereof	12/672,213	